Drug intelligence / Profile preview

CYT-338

Development stage: Preclinical
Lead developer: INVO BioScience
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CYT-338 is a CD38/NKp46 bispecific antibody developed for human therapeutic use, primarily targeting multiple myeloma. It is designed to engage natural killer (NK) cells via the NKp46 receptor and direct them to CD38-expressing cancer cells, aiming to induce NK cell-mediated cytotoxicity. This approach seeks to provide a safer alternative to CAR-T therapies for currently incurable cancers like multiple myeloma. The drug is being developed by NAYA Biosciences under an exclusive worldwide license agreement with Inserm Transfert.

Other names: NY 338NY338NY-338CYT 338CYT338CYT-338

Targets

CD38 (Cluster of Differentiation 38)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)NCR1 (Natural cytotoxicity triggering receptor 1)

Beyond the preview

Go deeper on CYT-338.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYT-338.